Implementing Evidence Based Treatment of Hypertension

Patients will be randomized to Pure control, intervention control, intervention group a,
intervention group b or intervention group c. Pure control patients will not receive any
study information about diuretics and their providers will not see any patients who receive
our study intervention letter. Patients in the intervention control group will not receive
the intervention but will see providers who have other patients in the intervention groups.
Patients in intervention group a will receive a customized letter prior to their next primary
care appointment with information regarding the patient's specific blood pressure, current
blood pressure medication and recommendation for switching or adding a thiazide. Patients in
group b will receive the customized intervention letter as well as a 20$ incentive for
discussing the information with their provider and a copay reimbursement for 6 months if a
prescription is written for a thiazide. Patients in group c will receive the intervention
letter, 20$ discussion incentive, copay reimbursement as well as a phone call reminder 1-2
days prior to their primary care visit.

Inclusion Criteria:

The eligible population includes patients less than 80 years of age enrolled in primary
care clinics at the study sites that meet the following additional inclusion criteria:

- No active prescription for a thiazide diuretic (or a medication that combines a
thiazide and another agent (e.g., hydrochlorothiazide and triamterene)

- Prior diagnosis of hypertension, as documented in VA outpatient administrative files

- Two or more visits to a primary care clinic in the prior 12 months;

- Blood pressure above treatment goal at the two most recent VA outpatient clinic visits
Above goal is defined as a systolic pressure >140 mmHg or diastolic pressure >90 mmHg.
For diabetics above goal is defined as systolic pressure >130 mmHg or diastolic
pressure >80 mmHg

- Blood pressure at goal (as defined above) during one of the last two outpatient clinic
visits, but the patient is receiving a prescription for a calcium channel blocker
(CCB)

Exclusion Criteria:

Patients meeting the above inclusion criteria will be excluded for the following reasons:

- Documented allergy to thiazides or to sulfa agents

- Previously documented intolerance or adverse drug reaction to thiazide diuretics

- Active prescription for a loop diuretic agent (e.g. furosemide)

- Renal insufficiency, defined by a glomerular filtration rate less than 30 ml/min

- No serum creatinine in the past year (to permit calculation of a creatinine clearance)

- Prior history of hypokalemia or serum potassium less than 3.5 meq/l in the prior year

- Diagnosis of gout or active prescription for allopurinol

- Congestive heart failure (CHF) due to systolic dysfunction with a documented left
ventricular ejection fraction < 35% by echocardiography, nuclear medicine study, or
ventriculography

- Residence in a long-term care facility

- No telephone for follow-up calls

- Life-expectancy < 6 months

- Inability to give informed consent or impaired cognitive function (defined as > 4
errors on the 10-item Pfeiffer Portable Mental Status Questionnaire82, administered
during study intake)